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Non-classic Cystic Fibrosis (CF) still represents a difficult entity to diagnose. We present a case of two sisters affected by mild pulmonary
symptoms started at puberty, carriers of the F508del mutation associated with the T5TG13 combination. We discuss the clinical utility of TG
repeat testing in individuals carrying the T5 variant. Furthermore, this case-report leads to reflect on the natural history of CF and the correct
management of its atypical forms.
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Diagnosis of classic Cystic Fibrosis (CF; OMIM #219700) is
easy because of multiple organ involvement and supported by a
positive sweat test. On the contrary, non-classic CF still represents
a difficult entity to define for clinicians, especially at the early
stage of the disease, due to its unusual presentation and/or late
onset of symptoms. Moreover, the sweat test may show border-
line or normal values and the diagnosis is mainly based on clinical
features and follow-up [1,2]. Genetic analysis of the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene
may identify one severe or mild mutation in trans with a 5
thymidines (T5) sequence within the intron 8 Splice Variant
(IVS8) region. T5 is responsible for an exacerbated skipping of
exon 9, decreasing the functional product levels. Its phenotypic
expression is variable [3] and influenced by another adjacent
polymorphic region, constituted by 9 to 13 TG repeats. The
relevance of TG repeats in influencing the T5 expression has been
demonstrated by Groman et al. [4] who showed that T5TG12 and
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affected subjects. Another study [5] confirmed that exon 9
splicing efficiency decreases as the number of TG repeats
increases, suggesting that altered splicing depended on changes in
RNA secondary structures.
1.1. Case report
A 23-year-old female, weight 58 Kg, height 176 cm, BMI
18.7 Kg/m2, with negative family history of CF, referred to our
centre because of chronic cough, previously treated unsuccess-
fully for asthmatic bronchitis. She suffered from three episodes
of pneumonia in the previous 5 years. Head and chest CT, after
the last pulmonary infection, revealed bilateral bronchiectasis
and pansinusitis. This finding suggested that the patient could
be affected by Kartagener Syndrome, successively excluded by
a ventilatory scintiscan that did not show a muco-ciliary
clearance delay. In our centre this patient was investigated to
ascertain the presence of CF; two different sweat tests showed
border-line chloride levels (46 and 51 mmol/L, respectively).
Therefore, it was performed genotype testing for the most
common CFTR gene mutations that revealed the presence of
F508del in trans with the T5TG13 and in cis with the T9TG10
combinations. DHPLC screening was also evaluated but it did
not reveal further CFTR mutations. Additionally, no grossd by Elsevier B.V. All rights reserved.
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method. Pulmonary function test showed a mild lung disease
(FEV1=3.36 L/s, 89.2% predicted). At follow-up the patient's
sputum culture was positive for Pseudomonas aeruginosa and
Staphylococcus aureus; these infections were treated with
specific antibiotics selected on the basis of the antibiogram. The
fecal elastase test resulted negative (N500 μg/g feces). These
data suggested a diagnosis of atypical CF without pancreatic
insufficiency.
We also studied the patient' sister, aged 18 years. At
presentation: weight 57 Kg, height 166 cm, BMI 20.7 Kg/m2.
She complained of mild symptoms (recurrent cough) indicating
a pulmonary involvement. She was pancreatic-sufficient and
did not refer any abdominal disorder. Chloride level at two
different sweat tests was border-line (34 and 35 mmol/L,
respectively) and the genetic investigation showed the same
pattern of her sister consisting in F508del in trans with the
T5TG13 and in cis with the T9TG10 combinations. The patient
underwent a chest CT which showed rare bronchiectasis in the
posterior segment of the lower lobe of both lungs. Spirometry
was normal, with a FEV1 of 3.55 L/s (118.1% predicted), and
the sputum culture resulted sterile.
To complete the genetic evaluation, both asymptomatic
parents were tested: the mother resulted homozygous for the T5
allele and carrier of a TG12TG13 combination; the father
resulted heterozygous for the F508del mutation, associated with
the T7 T9 combination.
2. Discussion
We report a case regarding two sisters carriers of the
F508del mutation associated with the T5TG13 combination.
Both present mild pulmonary symptoms started at puberty,
bronchiectasis, pancreatic sufficiency and border-line chloride
values revealed by the sweat test. However, they differ because
the elder patient has more evident bronchiectasis, and she also
presents pansinusitis, a positive sputum culture and a slightly
reduced FEV1. Our report confirms that the presence of T5
allele, in trans with a severe CFTR mutation, is associated
with non-classic CF and that TG13 variant acts as a real mild
mutation, enhancing the T5 penetrance and determining the
onset of a mild symptomatology in all patients. Thus, this
observation confirms the clinical utility of TG repeat testing in
individuals carrying the T5 variant, although it can not explain
the whole clinical variability seen in CF, as in our two patients
of our report. Phenotype could be influenced by other factors,
such as gender. Groman et al. showed that carriers of the
T5TG12 or T5TG13 alleles in trans with a CFTR mutation are
at higher risk of developing non-classic CF, if females, and
congenital bilateral absence of vas deferens, if males [4].
Similar differences have also been described in patients
carrying the F508del/R347H compound heterozygosis [6].
Furthermore, a gender gap exists in CF about survival, with
females having a significantly higher mortality than males [7],
persisting despite a consistent improvement in survival rates
through the years [8]. The reason of these differences is still
unknown; however, some authors have suggested that muta-tions in the Y chromosome could mitigate the CF phenotype in
males toward less severe manifestations, as an evolutionary
mechanism preserving fertility [9]; alternatively, it is possible
that CFTR gene reflects a tissue-specific expression according
to gender [10]. However, age difference between the two
patients appears the most likely cause of their phenotypic
variability. In fact, their age difference is of 5 years, a period of
time that could be sufficient to develop an advanced lung
disease in the elder sister. Therefore, an earlier diagnosis and a
close follow-up could probably avoid or delay the organ
deterioration in the younger sister.
The natural history of non-classic CF is poorly understood.
Studies on the Bronchoalveolar Lavage (BAL) technique in
infants with CF have provided more precise microbiological
data than upper airways cultures and relevant information about
the presence of inflammation, detected since four weeks of life,
even in the absence of infection [11,12]. The use of this invasive
approach may be justified in patients with classic CF but it is
unlikely applicable to those affected by atypical CF, given their
mild symptomatology and good prognosis. It is still unclear
when and how atypical CF starts and develops, and what kind of
prevention therapy is needed. However, CF has not to be
considered an “all or none disease” because chemical and/or
genetic CF markers may be asymptomatic for years and they
may or may not develop evidence of clinical disease [13].
Therefore, the evidence of a significant lung involvement, as
seen in the elder sister, suggests that a prevention therapy should
be necessary also in mild, non-classic CF.
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